A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

In S2, of the 33.3% of infants who received nirsevimab, 17.4% tested positive for RSV at admission. The mean age of these patients during nirsevimab administration was 36.6 days, whereas the mean ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Reduction in 2024-2025 RSV-associated hospitalization rates seen among infants aged 0 to 7 months with maternal vaccination or nirsevimab.

RSV-LRTI hospitalizations in infants younger than 6 months declined by 83.3% (95% CI, 70.9-95.8) during the period when nirsevimab was administered compared with those in the pre-pandemic periods ...

Vermont and New York are among the states with the highest RSV immunization rates in the country. Research published in late 2024 by JAMA Pediatrics found nirsevimab was more than 90% effective at ...

The FDA approved the maternal RSV vaccine and nirsevimab, a monoclonal antibody, within weeks of each other in 2023, making them available for the 2023-2024 respiratory disease season.

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu immunizations in 2025. The panel voted to expand RSV protection for infants ...

Three-quarters of infants were exposed to the maternal RSV vaccine or nirsevimab during their first RSV season. Younger mothers and Black mothers were less likely to receive the maternal vaccine.

The study could not assess nirsevimab's effectiveness in preventing RSV bronchiolitis in ambulatory care. Birth weight — a potential confounder — was not recorded.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.